Amid India’s toxic cough syrup scandal, WHO has flagged the danger of contaminated medicines being exported through unmonitored routes potentially exposing global markets to unsafe products.
Glimpse:
After toxic cough syrups were linked to child deaths in India, WHO raised concerns about illicit exports bypassing standard regulatory checks. Though the implicated syrups were not officially exported, the possibility of clandestine trade has triggered calls for stricter surveillance and cross-border coordination.
The World Health Organization has issued a cautionary note regarding the potential export of contaminated cough syrups via unregulated or informal trade routes. This comes after India declared three syrups Coldrif, Respifresh TR, and ReLife toxic due to diethylene glycol (DEG) contamination.
While none of these syrups are confirmed to have been officially exported, WHO warns that illicit channels could carry unsafe batches across international borders. The agency urged national drug regulators to initiate targeted surveillance in informal market segments, especially in countries with weaker oversight.
To preempt further spread, WHO recommended expanding random testing protocols, tracking distribution chains more tightly, and improving cross‐border data sharing on pharmaceutical safety alerts.
Karnataka state has already responded by testing 300–400 syrup samples; none were found substandard. The state also banned the suspect syrups locally and is developing an app for faster recall management.
“Unchecked exports of unsafe medicines are a public health hazard borders don’t stop toxicity.”
By
HB Team
Related News
